Matches in Wikidata for { <http://www.wikidata.org/entity/Q92616283> ?p ?o ?g. }
Showing items 1 to 44 of
44
with 100 items per page.
- Q92616283 description "artículu científicu espublizáu en payares de 2018" @default.
- Q92616283 description "im November 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q92616283 description "scientific article published on 30 November 2018" @default.
- Q92616283 description "wetenschappelijk artikel" @default.
- Q92616283 description "наукова стаття, опублікована в листопаді 2018" @default.
- Q92616283 name "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 name "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 type Item @default.
- Q92616283 label "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 label "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 prefLabel "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 prefLabel "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 P1433 Q92616283-C143AFBC-FC3A-4F98-B91A-2658DCBDBF14 @default.
- Q92616283 P1476 Q92616283-0A6273C0-9ADC-4278-B372-9F203DEAB865 @default.
- Q92616283 P2093 Q92616283-1125A660-901B-4F2E-9C30-2D0F80E22BF8 @default.
- Q92616283 P2093 Q92616283-28BA0ED1-B82E-428B-A7B7-10719ACBAAB1 @default.
- Q92616283 P2093 Q92616283-48BE4CF8-6DDB-4895-9CF0-933B667FB48C @default.
- Q92616283 P2093 Q92616283-B4FEFB1C-0A54-4007-8847-9C4E50B4B413 @default.
- Q92616283 P2093 Q92616283-B5AFCF9C-AB77-4A54-BDE3-BAE0AD881C97 @default.
- Q92616283 P2093 Q92616283-CC6A8E46-60DA-4FF7-A8C9-39CD085E8BC6 @default.
- Q92616283 P2093 Q92616283-DD3E9817-286E-4D2D-841E-76168A74B8CB @default.
- Q92616283 P31 Q92616283-45F713F8-09F8-433D-A3B1-4B9024165023 @default.
- Q92616283 P356 Q92616283-6ABE1999-3548-4B11-842E-91F33D45F0B6 @default.
- Q92616283 P577 Q92616283-49A9811A-6888-4B37-B441-93FB417F912B @default.
- Q92616283 P698 Q92616283-E0C0084A-CA1C-4CE2-8353-F2023766303D @default.
- Q92616283 P921 Q92616283-C1333A0C-A039-4D1E-80C6-AD60826723B3 @default.
- Q92616283 P921 Q92616283-C4FF2AFD-7598-4122-8C3C-7367ADBBB0A1 @default.
- Q92616283 P356 J.EUO.2018.11.006 @default.
- Q92616283 P698 31412002 @default.
- Q92616283 P1433 Q63882907 @default.
- Q92616283 P1476 "Cabozantinib for Progressive Metastatic Castration-resistant Prostate Cancer Following Docetaxel: Combined Analysis of Two Phase 3 Trials" @default.
- Q92616283 P2093 "Ethan M Basch" @default.
- Q92616283 P2093 "Gregory R Pond" @default.
- Q92616283 P2093 "Guru P Sonpavde" @default.
- Q92616283 P2093 "Howard I Scher" @default.
- Q92616283 P2093 "Johann S de Bono" @default.
- Q92616283 P2093 "Karim Fizazi" @default.
- Q92616283 P2093 "Matthew R Smith" @default.
- Q92616283 P31 Q13442814 @default.
- Q92616283 P356 "10.1016/J.EUO.2018.11.006" @default.
- Q92616283 P577 "2018-11-30T00:00:00Z" @default.
- Q92616283 P698 "31412002" @default.
- Q92616283 P921 Q420436 @default.
- Q92616283 P921 Q42824827 @default.